OKYO Pharma Ltd

OKYO Pharma Ltd operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It targets to cure and prevent the following conditions: dry eye disease, non-infectious anterior uveitis, allergic conjunctivitis, and ocular pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Ltd (NASDAQ:OKYO) announced it will present at the 10th International Tear Film & Ocular Surface Society (TFOS) Conference in Venice, Italy, being held from October 30 to November 2, 2024. Dr Raj Patil, OKYO's chief scientific officer, will present efficacy and safety data from the Phase 2 trial of OK-101, OKYO's leading candidate for treating dry eye disease (DED), on November 2.

OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference

OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob joined Proactive to discuss recent developments in the company's Phase 2 clinical trial for OK-101, an investigational therapy targeting neuropathic corneal pain (NCP). Jacob highlighted a significant milestone for the trial: the first patient dosed.

OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMI

OKYO Pharma Ltd (NASDAQ:OKYO) announced that the first patient has been dosed in the Phase 2 trial of its investigational therapeutic topical OK-101 to treat neuropathic corneal pain (NCP). NCP, which is believed to be caused by nerve damage to the cornea combined with inflammation, causes pain and sensitivity of the eyes, face or head.

OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial

LONDON and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat corneal neuropathic pain (NCP), an ocular condition associated with pain but without an FDA-approved therapy, is pleased to announce that the first patient has been dosed in the Phase 2 trial of topical ocular OK-101 to treat NCP. The Phase 2 study is designed as a double-masked, randomized, 12-week placebo-controlled trial in NCP patients. A total of 48 patients are planned to enroll for the study, with NCP disease confirmed via confocal microscopy.

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Ltd (NASDAQ:OKYO) has started recruiting patients for its Phase 2 trial of its ocular therapy OK-101, aimed at treating neuropathic corneal pain (NCP). The trial comes as part of OKYO's broader efforts to address unmet needs in the billion-dollar inflammatory dry eye disease (DED) market and NCP, an eye condition characterized by severe eye pain and sensitivity with no approved therapies.

OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment

OKYO Pharma Ltd (NASDAQ:OKYO) announced it has been granted a US patent covering claims on its investigational therapeutic OK-101's use to treat irritated, burning eyes and blurred vision in patients with dry eye disease (DED) The patent, issued on August 6, is US patent no. 12,053,503 titled “Methods for Treating Symptoms of Dry Eye Disease.

OKYO Pharma secures key US patent for dry eye disease therapy

SolarMax Technology Inc

ORLANDO, FL / ACCESSWIRE / August 23, 2024 / RedChip Companies will air interviews with OKYO Pharma Ltd. (Nasdaq:OKYO) and SolarMax Technology, Inc. (Nasdaq:SMXT) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 24, at 7 p.m.

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today an interview with its CEO, Dr. Gary S. Jacob will air on The RedChip Small Stocks, Big Money™ show on Bloomberg TV, this Saturday, August 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

OKYO Pharma CEO Interview to Air on Bloomberg TV

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 of the Company's ordinary shares on NASDAQ at a price of US$1.05 per share. This brings the total shareholding of Mr Cerrone to 9,721,570 shares which is 28.73% of issued share capital.

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has been notified that Panette Partners Limited, an entity in which its chairman Gabriele Cerrone has a beneficial interest, has purchased 35,000 shares of the company at $1 each. The company said the purchase brings Cerrone's total shareholding to 9,671,570 shares, or 28.58% of issued share capital.

OKYO Pharma chairman acquires more shares in the company

LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the company will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, which is being held on Thursday, August 15th.

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

OKYO Pharma Ltd (NASDAQ:OKYO) has been granted a European patent for its lead asset, OK-101. Entitled Compositions Comprising Chemerin Analogs and Methods of Use, it covers OK-101 chemerin analogs, strengthening the drug developer's intellectual property in ocular inflammatory and pain conditions.

OKYO Pharma lands European patent protection for lead asset

LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key European Patent entitled: “Compositions Comprising Chemerin Analogs and Methods of Use”. The present disclosure that lists Raj Patil, Chief Scientific Officer of OKYO Pharma as a joint Inventor, relates to novel OK-101 chemerin analogs for use in treating various diseases and conditions including but not limited to, ocular inflammatory and pain conditions, strengthening the Company's intellectual property position in this field.

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in the third quarter. In earlier studies, OK-101 showed significant pain relief for dry eye disease patients and reduced NCP in animal models.

OKYO Pharma dry eye disease trial to get underway in the third quarter

LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today its plan to advance OK-101 into a Phase 2 clinical trial of neuropathic corneal pain which is expected to begin in Q3 2024. This one-year study is supported by pre-clinical animal model data and statistically significant pain relief observed in OK-101's first human trial recently conducted in DED patients.

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

OKYO Pharma Ltd (NASDAQ:OKYO) has shared encouraging results from a phase II trial of its treatment candidate for dry eye disease. The study involved 240 patients and showed that 68% of them had improved by meeting both key measures: reduced conjunctival staining and ocular pain.

OKYO Pharma shares encouraging dry eye data

LONDON and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced promising new categorical data analyses from the recent OK-101 Phase 2 trial in DED patients. These analyses have identified conjunctival staining and ocular pain as the highest potential “sign” and “symptom” co-primary endpoints to be explored in the next DED trial of OK-101.

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at the Dry Horizons Symposium, a partner meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held May 3, 2024 in Seattle, WA.

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it is rescheduling its Key Opinion Leader event on the results of its Phase 2 trial of lead asset OK-101 in dry eye disease originally planned for April 9 until May 2024. The company said this would allow it to allow for the inclusion of additional analyses of its clinical data which it plans to present at upcoming ophthalmic conferences.

OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader event

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024. The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which it plans to present at upcoming ophthalmic conferences.

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

OKYO Pharma Ltd (NASDAQ:OKYO) unveiled new results showing its lead drug OK-101 has shown significant and measurable improvements in various indicators and symptoms associated with Dry Eye Disease (DED) during its initial Phase 2 trial involving human participants. These improvements include notably reducing ocular pain, which suggests potential efficacy in treating DED.

OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to host a Key Opinion Leader (KOL) event on April 9 following the anticipated release of comprehensive efficacy data from its Phase 2 trial of OK-101 in dry eye disease (DED) on March 22. The event, scheduled to start at 12pm ET is poised to offer a detailed exploration of the trial's findings, featuring presentations from renowned specialists, including Jay Pepose and Anat Galor.

OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease

- Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024. The event will feature Jay Pepose, MD, PhD, who will review details from the company's Phase 2 trial evaluating OK-101 in Dry Eye Disease, and Anat Galor, MD, MSPH who will discuss the unmet need for a topical treatment that improves ocular pain and differentiating features of OK-101.

News for OKYO Pharma Ltd Stock (OKYO)